, Volume 94, Issue 3, pp 342–346

1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane (DOI) exerts an anorexic action that is blocked by 5-HT2 antagonists in rats

  • L. E. Schechter
  • K. J. Simansky
Original Investigations

DOI: 10.1007/BF00174687

Cite this article as:
Schechter, L.E. & Simansky, K.J. Psychopharmacology (1988) 94: 342. doi:10.1007/BF00174687


Previous literature suggests that the anorexic action of peripherally administered serotonin (5-HT) is mediated by 5-HT2 receptors. This study, therefore, examined the effect of DOI, a non-indole 5-HT2 agonist, on deprivation-induced feeding. Rats were first adapted to a schedule in which a milk diet was presented for 6 h daily. Intraperitoneal (IP) administration of DOI (1.0–11.2 μmol/kg) inhibited feeding in a dose-related fashion (ID50=2.6 μmol/kg). One hour pretreatment with 6.0 μmol/kg of the 5-HT2 antagonists ketanserin and LY53857 completely reversed the anorexic action of an equimolar dose of DOI. Neither ketanserin nor LY53857, alone, altered baseline feeding. Further testing demonstrated the antagonistic effect of LY53857 (0.047–6.0 μmol/kg, IP) to be dose related, with an ID50 of 0.14 μmol/kg. Ten minute pretreatment with 1-(1-naphthyl)-piperazine (1-NP; 2.0 or 4.0 μmol/kg), a mixed-acting agent with 5HT2 blocking actions, also attenuated the anorexic effect of 6.0 μmol/kg DOI. Unlike ketanserin and LY53857, however, 1-NP did reduce food intake by itself. By contrast with ketanserin, LY53857 and 1-NP, the peripherally-acting 5-HT2 antagonist xylamidine failed to alter the anorexic effect of DOI. Taken together, these results suggest that central 5-HT2 receptors are important in the control of ingestive behavior.

Key words

1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane DOI 5-HT2 receptors LY53857 1-(1-naphthyl)piperazine 1-NP Ketanserin Xylamidine Feeding 

Copyright information

© Springer-Verlag 1988

Authors and Affiliations

  • L. E. Schechter
    • 1
  • K. J. Simansky
    • 1
  1. 1.Department of PharmacologyMedical College of Pennsylvania at Eastern Pennsylvania Psychiatric InstitutePhiladelphiaUSA

Personalised recommendations